Amplia has reached another recruitment milestone this week - enrolment for the second cohort of patients in our ACCENT trial in pancreatic cancer patients is now complete.
In line with the trial design, the second cohort is receiving an increased dose of AMP945, which is given in combination with standard gemcitabine/nab-paclitaxel chemotherapy. This first stage of the trial aims to identify the optimal dose of AMP945 for treating patients with advanced pancreatic cancer.
Dose escalation in further cohorts will be subject to authorisation by the Safety Committee, following review of clinical data.
Amplia’s CEO and Managing Director, Dr Chris Burns, said:
“We continue to make good progress in the ACCENT trial having recruited the three patients for Cohort 2 within one month of opening enrolment. We are extremely grateful to the patients and their loved ones, as well as the clinical trial sites in Melbourne, Sydney and Brisbane, for helping us progress this dose-escalation phase of the trial so efficiently.”
Read the ASX release.
